miR-371a-3p Predicting Viable Tumor in Patients Undergoing Retroperitoneal Lymph Node Dissection for Metastatic...

Area of Science:

• Oncology
• Molecular Biology
• Biomarker Discovery

Background:

• Metastatic germ cell tumors (GCTs) require accurate assessment of residual disease.
• Retroperitoneal lymph node dissection (RPLND) is a key surgical intervention.
• Novel biomarkers are needed to predict viable tumor post-RPLND.

Purpose of the Study:

• To evaluate the clinical utility of miR-371a-3p as a novel biomarker.
• To predict the presence of viable residual tumor in metastatic GCT patients undergoing RPLND.
• To compare miR-371a-3p performance against conventional serum tumor markers.

Main Methods:

• Prospective multicenter study (SWENOTECA-MIR) including 114 GCT patients.
• miR-371a-3p expression analyzed by RT-dDPCR pre- and post-RPLND.
• Comparison of miR-371a-3p with conventional markers and logistic regression analysis.
• Patients categorized into primary RPLND (seminoma/nonseminoma) and post-chemotherapy RPLND groups.

Main Results:

• In pre-chemotherapy seminomas, miR-371a-3p showed 74% sensitivity and 100% specificity for viable tumor.
• Pre-chemotherapy nonseminomas demonstrated lower sensitivity (34%) and specificity (88%) for miR-371a-3p.
• Post-chemotherapy, miR-371a-3p sensitivity was low (9%), decreasing to 0 in non-seminoma patients.
• miR-371a-3p levels decreased significantly after surgery in seminoma patients.

Conclusions:

• miR-371a-3p is a sensitive and specific marker for pre-chemotherapy seminomas, outperforming conventional markers.
• Utility of miR-371a-3p is limited in pre-chemotherapy nonseminomas and post-chemotherapy GCT patients.
• Further research may refine the role of miR-371a-3p in specific GCT contexts.